Dr. Reddy's Laboratories Q2 Earnings Call Highlights

DRL says cap on trade margins a positive, posts 36% dip in Q2 PAT

In the second quarter of FY2027, Dr. Reddy's Labs experienced a downturn in both revenue and profit. However, the company supports new trade margin regulations that aim to improve access to vital medicines. With a commitment to boosting its core business performance, management is also dedicated to exploring growth avenues.

Dr. Reddy's Laboratories Q2 Earnings Call Highlights

Dr. Reddy's Laboratories (NYSE:RDY) reported second-quarter FY2027 revenue of INR 8,671 crore, or $905 million, down 1.5% from a year earlier but up 7.4% sequentially, as lower North American lenalidomide sales offset growth in its underlying business. Chief Financial Officer M.V. Narasimham said t

Dr Reddy's Laboratories Ltd (RDY) (Q2 2027) Earnings Call Highlights: Margin Recovery in Focus ..

This article first appeared on GuruFocus. Consolidated Revenue: INR8,671 crore (USD905 million), down 1.5% YoY, up 7.4% QoQ. Gross Profit Margin: 52.1%, up 562 bps QoQ, down 254 bps YoY; Global Generics 56.2%, PSAI 11.8%. EBITDA Margin: 20.6% of revenues; EBITDA including other income…

Dr. Reddy’s Posts $1.747 Billion in Revenue for Six-Month Period Ended Sept. 30

For the second quarter alone, revenue was $905 million and diluted EPS was $0.12. The interim statements use IFRS, with U.S. dollar amounts presented as convenience translations.